

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:01:40 ON 27 MAY 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:02:26 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10506479\Struc 1.str



```

chain nodes :
19
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17
chain bonds :
1-6  4-12
ring bonds :
1-2  1-5  2-3  3-4  4-5  6-7  6-11  7-8  8-9  9-10  10-11  12-13  12-17  13-14
14-15  15-16  16-17
exact/norm bonds :
1-2  1-5  1-6  2-3  3-4  4-5
exact bonds :
4-12

```

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

G1:Cb,Cy,Hy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 20:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 10:02:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 58 TO ITERATE

100.0% PROCESSED 58 ITERATIONS

15 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 704 TO 1616

PROJECTED ANSWERS: 68 TO 532

L2 15 SEA SSS SAM L1

=> l1 full

FULL SEARCH INITIATED 10:02:45 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 956 TO ITERATE

100.0% PROCESSED 956 ITERATIONS

275 ANSWERS

SEARCH TIME: 00.00.01

L3 275 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 10:02:49 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> 13

L4 7 L3

=> d ibib abs hitstr 1-7

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:13335 CAPLUS

DOCUMENT NUMBER: 144:88182

TITLE: Preparation of tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
INVENTOR(S): Jirgensons, Aigars; Parsons, Christopher Graham Raphael; Jaunzeme, Ieva; Kalvinsh, Ivars; Henrich, Markus; Vanejevs, Maksims; Weil, Tanja; Kauss, Valerjans; Danysz, Wojciech

PATENT ASSIGNEE(S): Merz Pharma Gmbh & Co., Kgaa, Germany

SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 66,899.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20060004001	A1	20060105	US 2005-211829	20050825
US 20050197361	A1	20050908	US 2005-66899	20050225
PRIORITY APPLN. INFO.:			US 2004-548788P	P 20040227
			US 2005-66899	A2 20050225
OTHER SOURCE(S):		CASREACT 144:88182; MARPAT 144:88182		
GI				



AB Title compds. I [A = heteroaryl; R1 = (hetero)aryl; R2-5 = H, alkyl] are prepared For instance, II is prepared from 2-chloro-7,8-dihydro-6H-quinolin-5-one and 1,3-diphenyl-1H-pyrazole-5-boronic acid. Compds. of the invention have an EC50 range of about 0.5 nM to about 100 μ M for the mGluR5 receptor. I are group I mGluR modulators and useful for the control and prevention of chronic neurol. disorders.


IT 872423-58-0P, 2-[2-[3-(Pyridin-3-yl)-5-trifluoromethylphenyl]-2H-tetrazol-5-yl]-7,8-dihydro-6H-quinolin-5-one 872423-90-0P, 6,6-Dimethyl-2-[2-[3-(pyridin-3-yl)-5-trifluoromethylphenyl]-2H-tetrazol-5-yl]-7,8-dihydro-6H-quinolin-5-one 872423-91-1P, 7,7-Dimethyl-2-[2-[3-(pyridin-3-yl)-5-trifluoromethylphenyl]-2H-tetrazol-5-yl]-7,8-dihydro-6H-quinolin-5-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors)


RN 872423-58-0 CAPLUS

CN 5(6H)-Quinolinone, 7,8-dihydro-2-[2-[3-(3-pyridinyl)-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 872423-90-0 CAPLUS

CN 5(6H)-Quinolinone, 7,8-dihydro-6,6-dimethyl-2-[2-[3-(3-pyridinyl)-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 872423-91-1 CAPLUS
 CN 5(6H)-Quinolinone, 7,8-dihydro-7,7-dimethyl-2-[2-[3-(3-pyridinyl)-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1084937 CAPLUS
 DOCUMENT NUMBER: 143:415602
 TITLE: 3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: Identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists
 AUTHOR(S): Tehrani, Lida R.; Smith, Nicholas D.; Huang, Dehua; Poon, Steve F.; Roppe, Jeffrey R.; Seiders, Thomas Jon; Chapman, Deborah F.; Chung, Janice; Cramer, Merryl; Cosford, Nicholas D. P.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, San Diego, CA, 92121-1140, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(22), 5061-5064
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:415602
 AB Structure-activity relationship studies on the Ph ring of 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 2 led to the discovery that small, nonhydrogen bond donor substituents at the 3-position led to a substantial increase in in vitro potency. In particular, 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile (7) is a highly potent and selective mGlu5 receptor antagonist with good rat pharmacokinetics, brain penetration, and in vivo receptor occupancy.
 IT 605647-39-0 605648-47-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pyridine tetrazol substituted benzonitriles as highly potent and
selective metabotropic glutamate subtype 5 receptor antagonists)


RN 605647-39-0 CAPLUS

CN Pyridine, 2-[2-[3-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605648-47-3 CAPLUS

CN Pyridine, 2-[2-[3-fluoro-5-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA
INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:863089 CAPLUS

DOCUMENT NUMBER: 142:229

TITLE: Expedited SAR study of an mGluR5 antagonists:
generation of a focused library using a solution-phase
Suzuki coupling methodology

AUTHOR(S): Eastman, Brian; Chen, Chixu; Smith, Nicholas D.; Poon,
Steven; Chung, Janice; Reyes-Manalo, Grace; Cosford,
Nicholas D. P.; Munoz, Benito

CORPORATE SOURCE: Department of Chemistry, MRLSDB2, Merck Research
Laboratories, San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004),
14(22), 5485-5488

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:229

GI



I

AB The SAR of the lead compds. I (R = H) and I (R = F) was rapidly explored. Utilizing a parallel solution-phase Suzuki coupling approach, in tandem with strong cation exchange resin (SCX) purification afforded the desired focused library. The library was evaluated in vitro, a ninefold potency increase was achieved and the preference for ortho substitution of moderate steric bulk of the fourth, Ph ring was identified. In addition, dimethylisoxazole, as a heterocyclic replacement for the phenylic ring of the lead compound, was also identified by this approach.


IT 605647-35-6P 605648-37-1P 605649-51-2P
605649-58-9P 605649-80-7P 605650-04-2P
605650-10-0P 605650-14-4P 605650-42-8P
605651-95-4P 605652-06-0P 605652-19-5P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(phenyltetrazolylpyridines as mGluR5 antagonists)


RN 605647-35-6 CAPLUS

CN Pyridine, 2-[2-(2'-methoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605648-37-1 CAPLUS

CN Pyridine, 2-[2-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-51-2 CAPLUS

CN Pyridine, 2-[2-(2'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-58-9 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-2'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-80-7 CAPLUS

CN Pyridine, 2-[2-(2'-chloro-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-04-2 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-2'-methoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-10-0 CAPLUS

CN Pyridine, 2-[2-(2',5-difluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-14-4 CAPLUS

CN Pyridine, 2-[2-(2'-chloro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-42-8 CAPLUS

CN Pyridine, 2-[2-(2'-ethyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-95-4 CAPLUS

CN Pyridine, 2-[2-(2'-ethyl-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-06-0 CAPLUS

CN Pyridine, 2-[2-(5-fluoro[1,1':2',1''-terphenyl]-3-yl)-2H-tetrazol-5-yl]-
(9CI) (CA INDEX NAME)



RN 605652-19-5 CAPLUS

CN Pyridine, 2-(2-[1,1':2',1''-terphenyl]-3-yl)-2H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)




IT 605647-39-0P 605647-40-3P 605647-43-6P
605648-47-3P 605649-60-3P 605649-64-7P
605649-66-9P 605649-74-9P 605649-78-3P
605649-86-3P 605649-88-5P 605649-90-9P
605649-96-5P 605649-98-7P 605650-20-2P
605650-22-4P 605650-26-8P 605650-44-0P
605650-46-2P 605650-51-9P 605650-57-5P
605650-69-9P 605650-75-7P 605650-79-1P
605650-87-1P 605650-91-7P 605650-99-5P
605651-03-4P 605651-04-5P 605651-06-7P
605651-91-0P 605651-96-5P 605652-00-4P
605652-07-1P 605652-12-8P 605652-16-2P
793726-49-5P 793726-60-0P 793726-63-3P
793726-68-8P 793726-71-3P 793726-72-4P
793726-73-5P 793726-74-6P 793726-75-7P
793726-76-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(phenyltetrazolylpyridines as mGluR5 antagonists)


RN 605647-39-0 CAPLUS

CN Pyridine, 2-[2-[3-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-40-3 CAPLUS

CN Pyridine, 2-[2-[3-(4-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-43-6 CAPLUS

CN Pyrimidine, 2-methoxy-5-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-47-3 CAPLUS

CN Pyridine, 2-[2-[3-fluoro-5-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-60-3 CAPLUS

CN Pyridine, 2-[2-(4',5-difluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-64-7 CAPLUS

CN Pyridine, 2-[2-[3-fluoro-5-(4-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-66-9 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-4'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605649-74-9 CAPLUS

CN Pyridine, 2-[2-(4'-chloro-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605649-78-3 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-2',6'-dimethyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605649-86-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxaldehyde, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
(CA INDEX NAME)




RN 605649-88-5 CAPLUS

CN Pyridine, 2-[2-(3'-chloro-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605649-90-9 CAPLUS

CN [1,1'-Biphenyl]-2-ol, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
(CA INDEX NAME)




RN 605649-96-5 CAPLUS

CN Pyridine, 2-[2-(3',5-difluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA
INDEX NAME)




RN 605649-98-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
(CA INDEX NAME)




RN 605650-20-2 CAPLUS

CN Pyridine, 2-[2-(4'-methoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-22-4 CAPLUS

CN Pyridine, 2-[2-(3'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-26-8 CAPLUS

CN Pyridine, 2-[2-(3'-chloro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-44-0 CAPLUS


CN Pyridine, 2-[2-(2',5'-difluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-46-2 CAPLUS
 CN Ethanone, 1-[3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]][1,1'-biphenyl]-2-yl]-
 (CA INDEX NAME)




RN 605650-51-9 CAPLUS
 CN [1,1'-Biphenyl]-2-ol, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX
 NAME)




RN 605650-57-5 CAPLUS
 CN Pyridine, 2-[2-(2'-ethoxy-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605650-69-9 CAPLUS
 CN Pyridine, 2-[2-(5-fluoro-2'-phenoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605650-75-7 CAPLUS
CN Pyrimidine, 5-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605650-79-1 CAPLUS
CN Pyrimidine, 5-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-2-methoxy- (CA INDEX NAME)



RN 605650-87-1 CAPLUS
CN Pyridine, 2-[2-(2',5,6'-trifluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-91-7 CAPLUS
CN Pyridine, 2-[2-(2'-methoxy-5'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-99-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 605651-03-4 CAPLUS

CN Pyridine, 2-[2-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-04-5 CAPLUS

CN Pyridine, 2-[2-(2'-phenoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-06-7 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-2'-nitro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-91-0 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-3'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-96-5 CAPLUS

CN Pyridine, 2-[2-(4'-chloro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA
INDEX NAME)




RN 605652-00-4 CAPLUS

CN Pyridine, 2-[2-(2',6'-dimethyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605652-07-1 CAPLUS


CN Pyridine, 2-[2-[5-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2H-
tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-12-8 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 605652-16-2 CAPLUS
 CN Pyridine, 2-[2-(2'-ethoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 793726-49-5 CAPLUS
 CN Pyridine, 2-[2-(2',6'-difluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 793726-60-0 CAPLUS
 CN Pyridine, 2-[2-[2'-(phenylmethoxy)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 793726-63-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
(CA INDEX NAME)




RN 793726-68-8 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-,
methyl ester (CA INDEX NAME)




RN 793726-71-3 CAPLUS

CN Pyridine, 2-[2-[3-(3,5-dimethyl-4-isoxazolyl)phenyl]-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 793726-72-4 CAPLUS


CN Pyridine, 2-[2-[3-(3-phenyl-5-isoxazolyl)phenyl]-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 793726-73-5 CAPLUS
 CN Pyridine, 2-[2-[3-(2-furanyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 793726-74-6 CAPLUS
 CN Pyridine, 2-[2-[3-(3,5-dimethyl-4-isoxazolyl)-5-fluorophenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 793726-75-7 CAPLUS
 CN Pyridine, 2-[2-[3-fluoro-5-(3-phenyl-5-isoxazolyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 793726-76-8 CAPLUS
 CN Pyridine, 2-[2-[3-fluoro-5-(2-furanyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




IT 605647-32-3 605649-56-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phenyltetrazolylpyridines as mGluR5 antagonists)


RN 605647-32-3 CAPLUS

CN Pyridine, 2-(2-[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl)- (CA INDEX NAME)



RN 605649-56-7 CAPLUS

CN Pyridine, 2-[2-(5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:863088 CAPLUS

DOCUMENT NUMBER: 142:228

TITLE: Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity

AUTHOR(S): Smith, Nicholas D.; Poon, Steve F.; Huang, Dehua; Green, Mitchell; King, Christopher; Tehrani, Lida; Roppe, Jeffrey R.; Chung, Janice; Chapman, Deborah P.; Cramer, Meryll; Cosford, Nicholas D. P.

CORPORATE SOURCE: Department of Medicinal Chemistry, MRLSDB2, Merck Research Laboratories, San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(22), 5481-5484

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:228

GI




AB Structure-activity relationship studies focused on bio-isosteric replacements of 2-pyridyl resulted in mGlu5 receptor antagonists with reduced inhibition of cytochrome P 450 1A2. This led to highly potent, selective and orally bioavailable 2-imidazolyl tetrazoles such as I that are devoid of cytochrome P 450 inhibitory activity.

IT 605648-69-9P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P 450 1A2 inhibitory activity)

RN 605648-69-9 CAPLUS

CN Pyridine, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-4-methyl- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:863087 CAPLUS

DOCUMENT NUMBER: 142:38203

TITLE: 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist

AUTHOR(S): Poon, Steve F.; Eastman, Brian W.; Chapman, Deborah F.; Chung, Janice; Cramer, Merryl; Holtz, Gregory; Cosford, Nicholas D. P.; Smith, Nicholas D.


CORPORATE SOURCE: Department of Medicinal Chemistry, MRLSDB2, Merck Research Laboratories, San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(22), 5477-5480

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:38203
 GI




AB Structure-activity relationship studies performed around 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile (I, R = CN) for the purpose of developing novel mGlu5 receptor antagonists are described. Synthesis of a series of four-ring tetrazoles led to the discovery of 3-[3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine (I, R = 4-Me-3-pyridyl), a highly potent, brain penetrant, azole-based mGlu5 receptor antagonist.

IT 605648-69-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, mGlu5 receptor antagonist activity and structure-activity relationship of [fluoro(pyridinyltetrazolyl)phenyl]methylpyridines)

RN 605648-69-9 CAPLUS

CN Pyridine, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-4-methyl- (CA INDEX NAME)




IT 605648-45-1P 605648-47-3P 605648-49-5P
 605648-57-5P 605648-59-7P 605648-63-3P
 605648-67-7P 605648-75-7P 605648-79-1P
 605648-81-5P 605649-56-7P 605649-58-9P
 605649-64-7P 605649-66-9P 605649-70-5P
 605651-91-0P 807620-98-0P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, mGlu5 receptor antagonist activity and structure-activity relationship of [fluoro(pyridinyltetrazolyl)phenyl]methylpyridines)

RN 605648-45-1 CAPLUS


CN [1,1'-Biphenyl]-2-carbonitrile, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-

2-yl]- (CA INDEX NAME)




RN 605648-47-3 CAPLUS

CN Pyridine, 2-[2-[3-fluoro-5-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605648-49-5 CAPLUS

CN [1,1'-Biphenyl]-2-amine, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)



RN 605648-57-5 CAPLUS


CN 3-Pyridinamine, 2-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)



RN 605648-59-7 CAPLUS


CN Pyridine, 2-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-3-methyl-

(CA INDEX NAME)




RN 605648-63-3 CAPLUS

CN 4-Pyridinamine, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-
(CA INDEX NAME)




RN 605648-67-7 CAPLUS

CN Pyridine, 4-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-3-methyl-
(CA INDEX NAME)




RN 605648-75-7 CAPLUS

CN Pyridine, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-2-methyl-
(CA INDEX NAME)




RN 605648-79-1 CAPLUS

CN Pyridine, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-5-methyl-
(CA INDEX NAME)




RN 605648-81-5 CAPLUS

CN Pyridine, 5-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-2-methyl-
(CA INDEX NAME)




RN 605649-56-7 CAPLUS

CN Pyridine, 2-[2-(5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA
INDEX NAME)




RN 605649-58-9 CAPLUS


CN Pyridine, 2-[2-(5-fluoro-2'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605649-64-7 CAPLUS
 CN Pyridine, 2-[2-[3-fluoro-5-(4-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-66-9 CAPLUS
 CN Pyridine, 2-[2-(5-fluoro-4'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-70-5 CAPLUS
 CN [1,1'-Biphenyl]-3-carbonitrile, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605651-91-0 CAPLUS
 CN Pyridine, 2-[2-(5-fluoro-3'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 807620-98-0 CAPLUS
 CN Pyridine, 2-[2-[3-fluoro-5-(2-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



IT 807620-97-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, mGlu5 receptor antagonist activity and structure-activity relationship of [fluoro(pyridinyltetrazolyl)phenyl]methylpyridines)
 RN 807620-97-9 CAPLUS
 CN Pyridine, 2-[2-[3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2004:863086 CAPLUS

DOCUMENT NUMBER: 142:32440

TITLE: 2-{2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist


AUTHOR(S): Huang, Dehua; Poon, Steve F.; Chapman, Deborah F.; Chung, Janice; Cramer, Merryl; Reger, Thomas S.; Roppe, Jeffrey R.; Tehrani, Lida; Cosford, Nicholas D. P.; Smith, Nicholas D.

CORPORATE SOURCE: Department of Medicinal Chemistry, MRLSDB2, Merck
 Research Laboratories, San Diego, CA, 92121, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004),
 14(22), 5473-5476
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:32440
 GI



I

AB Structure-activity relationship studies on 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile led to the discovery of 2-{2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl}pyridine (I) - a highly potent and selective mGlu5 receptor antagonist with good brain penetration and in vivo receptor occupancy in rat and cross-species oral bioavailability.
 IT 605648-28-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pyridinyltetrazolylpyridines as metabotropic glutamate receptor antagonists)
 RN 605648-28-0 CAPLUS
 CN 1H-Pyrrolo[2,3-c]pyridine, 1-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:757524 CAPLUS

DOCUMENT NUMBER: 139:276903

TITLE: Preparation of diaryltetrazoles as modulators of metabotropic glutamate receptor-5

INVENTOR(S): Smith, Nicholas D.; Cosford, Nicholas D. P.; Reger, Thomas R.; Roppe, Jeffrey R.; Poon, Steven F.; Huang, Dehua; Chen, Chixu; Eastman, Brian W.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 170 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077918	A1	20030925	WO 2003-US7074	20030307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478799	A1	20030925	CA 2003-2478799	20030307
AU 2003213783	A1	20030929	AU 2003-213783	20030307
AU 2003213783	B2	20070125		
EP 1485093	A1	20041215	EP 2003-711474	20030307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005526081	T	20050902	JP 2003-575971	20030307
US 20050153986	A1	20050714	US 2004-506479	20040901
PRIORITY APPLN. INFO.:			US 2002-363456P	P 20020312
			WO 2003-US7074	W 20030307
OTHER SOURCE(S):	MARPAT	139:276903		
GI				



AB Tetrazoles I [A, B = alkylene, optionally interrupted by heteroatoms; X, Y = (un)substituted heteroaryl, at least one of which has N adjacent to the attachment to A or B] are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. I IC₅₀ ≤ 10 μM in the calcium flux assay and ≤ 100 μM in the phosphatidylinositol hydrolysis assay. Thus, 1-(3-aminophenyl)-3-methyl-2-imidazolidinone was diazotized and treated with 2-pyridinecarboxaldehyde and 4-MeC₆H₄SO₂NHNH₂ to give the tetrazole II.


IT 605647-20-9P 605647-21-0P 605647-22-1P
 605647-23-2P 605647-24-3P 605647-25-4P
 605647-26-5P 605647-27-6P 605647-29-8P
 605647-30-1P 605647-32-3P 605647-33-4P
 605647-34-5P 605647-35-6P 605647-36-7P
 605647-37-8P 605647-38-9P 605647-39-0P
 605647-40-3P 605647-41-4P 605647-42-5P
 605647-43-6P 605647-44-7P 605647-45-8P
 605647-46-9P 605647-47-0P 605647-48-1P
 605647-49-2P 605647-50-5P 605647-51-6P
 605647-52-7P 605647-54-9P 605647-55-0P
 605647-56-1P 605647-57-2P 605647-58-3P
 605647-59-4P 605647-60-7P 605647-62-9P
 605647-63-0P 605647-66-3P 605647-68-5P
 605647-72-1P 605647-74-3P 605647-76-5P
 605647-94-7P 605647-96-9P 605647-98-1P
 605648-00-8P 605648-02-0P 605648-04-2P
 605648-06-4P 605648-07-5P 605648-09-7P
 605648-11-1P 605648-16-6P 605648-20-2P
 605648-26-8P 605648-28-0P 605648-30-4P
 605648-32-6P 605648-35-9P 605648-37-1P
 605648-39-3P 605648-41-7P 605648-43-9P
 605648-45-1P 605648-47-3P 605648-49-5P
 605648-50-8P 605648-51-9P 605648-53-1P
 605648-55-3P 605648-57-5P 605648-59-7P
 605648-61-1P 605648-63-3P 605648-65-5P

605648-67-7P 605648-69-9P 605648-71-3P
605648-75-7P 605648-79-1P 605648-81-5P
605648-83-7P 605648-89-3P 605648-91-7P
605649-01-2P 605649-03-4P 605649-07-8P
605649-09-0P 605649-51-2P 605649-54-5P
605649-56-7P 605649-58-9P 605649-60-3P
605649-62-5P 605649-64-7P 605649-66-9P
605649-68-1P 605649-70-5P 605649-72-7P
605649-74-9P 605649-76-1P 605649-78-3P
605649-80-7P 605649-82-9P 605649-84-1P
605649-86-3P 605649-88-5P 605649-90-9P
605649-92-1P 605649-94-3P 605649-96-5P
605649-98-7P 605650-00-8P 605650-02-0P
605650-04-2P 605650-06-4P 605650-08-6P
605650-10-0P 605650-12-2P 605650-14-4P
605650-16-6P 605650-18-8P 605650-20-2P
605650-22-4P 605650-24-6P 605650-26-8P
605650-28-0P 605650-30-4P 605650-32-6P
605650-34-8P 605650-36-0P 605650-38-2P
605650-40-6P 605650-42-8P 605650-44-0P
605650-46-2P 605650-48-4P 605650-51-9P
605650-53-1P 605650-57-5P 605650-59-7P
605650-61-1P 605650-63-3P 605650-65-5P
605650-67-7P 605650-69-9P 605650-71-3P
605650-75-7P 605650-79-1P 605650-83-7P
605650-85-9P 605650-87-1P 605650-89-3P
605650-91-7P 605650-93-9P 605650-95-1P
605650-97-3P 605650-99-5P 605651-01-2P
605651-03-4P 605651-04-5P 605651-05-6P
605651-06-7P 605651-08-9P 605651-13-6P
605651-15-8P 605651-17-0P 605651-19-2P
605651-21-6P 605651-23-8P 605651-25-0P
605651-27-2P 605651-28-3P 605651-30-7P
605651-32-9P 605651-33-0P 605651-34-1P
605651-36-3P 605651-37-4P 605651-38-5P
605651-40-9P 605651-42-1P 605651-43-2P
605651-47-6P 605651-49-8P 605651-50-1P
605651-51-2P 605651-52-3P 605651-54-5P
605651-55-6P 605651-56-7P 605651-57-8P
605651-88-5P 605651-89-6P 605651-90-9P
605651-91-0P 605651-92-1P 605651-93-2P
605651-94-3P 605651-95-4P 605651-96-5P
605651-97-6P 605651-98-7P 605651-99-8P
605652-00-4P 605652-01-5P 605652-02-6P
605652-03-7P 605652-04-8P 605652-05-9P
605652-06-0P 605652-07-1P 605652-08-2P
605652-09-3P 605652-10-6P 605652-11-7P
605652-12-8P 605652-13-9P 605652-14-0P
605652-15-1P 605652-16-2P 605652-17-3P
605652-18-4P 605652-19-5P 605652-20-8P
605652-21-9P 605652-22-0P 605652-23-1P
605652-24-2P 605652-25-3P 605652-26-4P
605652-27-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryltetrazoles as inhibitors of metabotropic glutamate receptor-5)


RN 605647-20-9 CAPLUS

CN 2-Imidazolidinone, 1-methyl-3-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-
(CA INDEX NAME)




RN 605647-21-0 CAPLUS

CN Pyridine, 2-[2-[4-(2-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-22-1 CAPLUS

CN Pyridine, 2-[2-[4-(4-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-23-2 CAPLUS

CN Pyridine, 2-[2-[3-(1H-imidazol-1-yl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-24-3 CAPLUS


CN Pyrazine, 2-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605647-25-4 CAPLUS
 CN Morpholine, 3-[4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605647-26-5 CAPLUS
 CN Pyridine, 2-[2-[3-(2H-tetrazol-5-yl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-27-6 CAPLUS
 CN Benzonitrile, 2-(2-pyridinyl)-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605647-29-8 CAPLUS
 CN Pyridine, 2-[2-(2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-30-1 CAPLUS
CN Pyridine, 2-[2-[3-methyl-4-(2-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-32-3 CAPLUS
CN Pyridine, 2-(2-[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl)- (CA INDEX NAME)



RN 605647-33-4 CAPLUS
CN Pyridine, 2-(2-[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl)- (CA INDEX NAME)




RN 605647-34-5 CAPLUS
CN Pyridine, 2-[2-[3-(1H-pyrazol-1-yl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-35-6 CAPLUS

CN Pyridine, 2-[2-(2'-methoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-36-7 CAPLUS

CN Pyrimidine, 5-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605647-37-8 CAPLUS

CN [1,1'-Biphenyl]-3-amine, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605647-38-9 CAPLUS

CN Pyridine, 2-[2-[3-(2-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-39-0 CAPLUS


CN Pyridine, 2-[2-[3-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-40-3 CAPLUS
CN Pyridine, 2-[2-[3-(4-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-41-4 CAPLUS
CN Pyridine, 2-[2-[3-(3-thienyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-42-5 CAPLUS
CN Pyridine, 2-[2-[3-(2-thienyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605647-43-6 CAPLUS
CN Pyrimidine, 2-methoxy-5-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605647-44-7 CAPLUS
CN Pyridine, 2-methoxy-5-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605647-45-8 CAPLUS

CN Pyridine, 2-[2-[3-chloro-4-(2-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-46-9 CAPLUS

CN Pyridine, 2-[2-[3-methoxy-4-(2-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-47-0 CAPLUS

CN Pyridine, 2-[2-[3-methoxy-4-(2-thiazolyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-48-1 CAPLUS


CN Pyridine, 2-[2-[3-chloro-5-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-49-2 CAPLUS
 CN Pyridine, 2-[2-[4-methoxy-3-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-50-5 CAPLUS
 CN Pyridine, 2-[2-[4-(1H-pyrazol-1-yl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-51-6 CAPLUS
 CN Morpholine, 4-[2-chloro-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605647-52-7 CAPLUS
 CN Pyridine, 2-[2-[2-chloro-5-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-54-9 CAPLUS
 CN Pyridine, 2-[2-[3-fluoro-4-(2-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-55-0 CAPLUS
 CN Benzoic acid, 2-(2-pyridinyl)-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)



RN 605647-56-1 CAPLUS
 CN Pyridine, 2-[2-(3'-methoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-57-2 CAPLUS
 CN Pyrimidine, 2-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605647-58-3 CAPLUS

CN [1,1'-Biphenyl]-3-carbonitrile, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
(CA INDEX NAME)




RN 605647-59-4 CAPLUS

CN Pyridine, 2-[2-[3-(2-thiazolyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-60-7 CAPLUS

CN Pyridine, 2-[2-(2'-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605647-62-9 CAPLUS

CN [1,1'-Biphenyl]-2-amine, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605647-63-0 CAPLUS

CN [1,1'-Biphenyl]-2-amine, 4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605647-66-3 CAPLUS

CN [1,1'-Biphenyl]-2-amine, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605647-68-5 CAPLUS

CN Pyridine, 2-[2-[3-methoxy-4-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605647-72-1 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine, 1-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)



RN 605647-74-3 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine, 1-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-

yl]phenyl]- (CA INDEX NAME)




RN 605647-76-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2-fluoro-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605647-94-7 CAPLUS

CN Pyrimidine, 2-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605647-96-9 CAPLUS

CN 3-Pyridinamine, 2-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605647-98-1 CAPLUS


CN 3-Pyridinecarboxamide, 2-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-00-8 CAPLUS
 CN 3-Pyridinecarbonitrile, 2-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-02-0 CAPLUS
 CN 2-Pyrazinecarbonitrile, 3-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)



RN 605648-04-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carbonitrile, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605648-06-4 CAPLUS
 CN [1,1'-Biphenyl]-4-carbonitrile, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605648-07-5 CAPLUS

CN Pyridine, 2-methoxy-6-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-09-7 CAPLUS

CN Pyridine, 2-[2-[3-methyl-5-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605648-11-1 CAPLUS

CN Pyridine, 2-[2-[2-bromo-5-methoxy-4-(2-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605648-16-6 CAPLUS


CN Pyridine, 2-[2-(3-pyridinyloxy)-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-20-2 CAPLUS
 CN Pyridine, 2-[2-[3-(2H-1,2,3-triazol-2-yl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605648-26-8 CAPLUS
 CN 1H-Pyrrolo[2,3-c]pyridine, 1-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-28-0 CAPLUS
 CN 1H-Pyrrolo[2,3-c]pyridine, 1-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-30-4 CAPLUS
 CN 3H-Imidazo[4,5-c]pyridine, 3-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-32-6 CAPLUS
 CN 1H-Pyrrolo[2,3-c]pyridine, 1-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-35-9 CAPLUS
 CN Quinoline, 8-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-37-1 CAPLUS
 CN Pyridine, 2-[2-[2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605648-39-3 CAPLUS
 CN 4-Pyridinamine, 3-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-41-7 CAPLUS
 CN 2-Pyridinamine, 3-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-43-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605648-45-1 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605648-47-3 CAPLUS
 CN Pyridine, 2-[2-[3-fluoro-5-(3-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605648-49-5 CAPLUS
 CN [1,1'-Biphenyl]-2-amine, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
 (CA INDEX NAME)




RN 605648-50-8 CAPLUS
 CN Pyridine, 2-chloro-3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-
 (CA INDEX NAME)




RN 605648-51-9 CAPLUS
 CN Pyridine, 2-[2-(2'-bromo-5'-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605648-53-1 CAPLUS
 CN Pyridine, 2-methoxy-3-[3-methoxy-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-
 (CA INDEX NAME)




RN 605648-55-3 CAPLUS
 CN [1,1'-Biphenyl]-2-carbonitrile, 5-fluoro-3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)



RN 605648-57-5 CAPLUS
 CN 3-Pyridinamine, 2-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-59-7 CAPLUS
 CN Pyridine, 2-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-3-methyl- (CA INDEX NAME)




RN 605648-61-1 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 3,3'-difluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605648-63-3 CAPLUS

CN 4-Pyridinamine, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-65-5 CAPLUS

CN 2-Pyridinamine, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605648-67-7 CAPLUS

CN Pyridine, 4-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-3-methyl- (CA INDEX NAME)




RN 605648-69-9 CAPLUS

CN Pyridine, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-4-methyl-
(CA INDEX NAME)




RN 605648-71-3 CAPLUS

CN 2-Pyridinecarbonitrile, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-
(CA INDEX NAME)




RN 605648-75-7 CAPLUS

CN Pyridine, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-2-methyl-
(CA INDEX NAME)




RN 605648-79-1 CAPLUS


CN Pyridine, 3-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-5-methyl-
(CA INDEX NAME)




RN 605648-81-5 CAPLUS
 CN Pyridine, 5-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-2-methyl-
 (CA INDEX NAME)



RN 605648-83-7 CAPLUS
 CN Pyridine, 2-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-5-methyl-
 (CA INDEX NAME)




RN 605648-89-3 CAPLUS
 CN Pyridine, 2-[2-(2,2'-dimethoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605648-91-7 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605649-01-2 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605649-03-4 CAPLUS

CN Pyridine, 2-[2-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-07-8 CAPLUS

CN Pyridine, 2-[4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 605649-09-0 CAPLUS


CN Pyridine, 2-[4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 605649-51-2 CAPLUS
 CN Pyridine, 2-[2-(2-(2'-methoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl)]- (CA INDEX NAME)




RN 605649-54-5 CAPLUS
 CN Pyridine, 2-[2-(2-(4'-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl)]- (CA INDEX NAME)




RN 605649-56-7 CAPLUS
 CN Pyridine, 2-[2-(2-(5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl)]- (CA INDEX NAME)




RN 605649-58-9 CAPLUS
 CN Pyridine, 2-[2-(2-(5-fluoro-2'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl)]- (CA INDEX NAME)




RN 605649-60-3 CAPLUS
 CN Pyridine, 2-[2-(4',5-difluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-62-5 CAPLUS
 CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 605649-64-7 CAPLUS
 CN Pyridine, 2-[2-[3-fluoro-5-(4-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-66-9 CAPLUS
 CN Pyridine, 2-[2-(5-fluoro-4'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-68-1 CAPLUS
 CN Pyridine, 2-[2-(2',3'-dichloro-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605649-70-5 CAPLUS
 CN [1,1'-Biphenyl]-3-carbonitrile, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605649-72-7 CAPLUS
 CN Pyridine, 2-[2-(2',5,5'-trifluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-74-9 CAPLUS
 CN Pyridine, 2-[2-(4'-chloro-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-

(CA INDEX NAME)




RN 605649-76-1 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-2',4'-dimethoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-78-3 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-2',6'-dimethyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-80-7 CAPLUS

CN Pyridine, 2-[2-(2'-chloro-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-82-9 CAPLUS

CN Ethanone, 1-[3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 605649-84-1 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-2',3'-dimethyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-86-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxaldehyde, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605649-88-5 CAPLUS

CN Pyridine, 2-[2-(3'-chloro-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605649-90-9 CAPLUS

CN [1,1'-Biphenyl]-2-ol, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
(CA INDEX NAME)




RN 605649-92-1 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-2',5'-dimethyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605649-94-3 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-3'-methoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605649-96-5 CAPLUS

CN Pyridine, 2-[2-(3',5-difluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA
INDEX NAME)




RN 605649-98-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605650-00-8 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-3'-nitro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-02-0 CAPLUS

CN Pyridine, 2-[2-(3',5'-dichloro-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-04-2 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-2'-methoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-06-4 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-fluoro-N,N-dimethyl-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605650-08-6 CAPLUS

CN Pyridine, 2-[2-(2',4',5-trifluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-10-0 CAPLUS

CN Pyridine, 2-[2-(2',5-difluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-12-2 CAPLUS

CN Pyridine, 2-[2-[3-(1,3-benzodioxol-5-yl)-5-fluorophenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-14-4 CAPLUS

CN Pyridine, 2-[2-(2'-chloro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-16-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxaldehyde, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605650-18-8 CAPLUS

CN Pyridine, 2-[2-(3'-nitro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-20-2 CAPLUS

CN Pyridine, 2-[2-(4'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-22-4 CAPLUS

CN Pyridine, 2-[2-(3'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-24-6 CAPLUS

CN Ethanone, 1-[3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-3-yl]-
(CA INDEX NAME)




RN 605650-26-8 CAPLUS

CN Pyridine, 2-[2-(3'-chloro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA
INDEX NAME)




RN 605650-28-0 CAPLUS

CN Pyridine, 2-[2-(3'-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA
INDEX NAME)




RN 605650-30-4 CAPLUS

CN Pyridine, 2-[2-(3',5'-dichloro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605650-32-6 CAPLUS

CN Pyridine, 2-[2-(2',4'-difluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605650-34-8 CAPLUS

CN Pyridine, 2-[2-(2',3'-dichloro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605650-36-0 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605650-38-2 CAPLUS

CN Pyridine, 2-[2-(2',3'-dimethyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605650-40-6 CAPLUS


CN Pyridine, 2-[2-(2',5'-dimethyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605650-42-8 CAPLUS
 CN Pyridine, 2-[2-(2'-ethyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-44-0 CAPLUS
 CN Pyridine, 2-[2-(2',5'-difluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-46-2 CAPLUS
 CN Ethanone, 1-[3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-2-yl]- (CA INDEX NAME)




RN 605650-48-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605650-51-9 CAPLUS
CN [1,1'-Biphenyl]-2-ol, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605650-53-1 CAPLUS
CN Pyridine, 2-[2-(2'-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-57-5 CAPLUS
CN Pyridine, 2-[2-(2'-ethoxy-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-59-7 CAPLUS
CN Pyridine, 2-[2-(5-fluoro-2'-methoxy-5'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-61-1 CAPLUS
 CN Pyridine, 2-[2-[5-fluoro-2'-(methylthio)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605650-63-3 CAPLUS
 CN Acetamide, N-[3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 605650-65-5 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 605650-67-7 CAPLUS

CN Pyridine, 2-[2-[3-(4-dibenzofuranyl)-5-fluorophenyl]-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605650-69-9 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-2'-phenoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605650-71-3 CAPLUS

CN Pyridine, 2-[2-[5-fluoro-2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-2H-
tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-75-7 CAPLUS


CN Pyrimidine, 5-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA
INDEX NAME)




RN 605650-79-1 CAPLUS
 CN Pyrimidine, 5-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 605650-83-7 CAPLUS
 CN Pyridine, 2-[2-[5-fluoro-3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605650-85-9 CAPLUS
 CN Pyridine, 2-[2-[5-fluoro-2'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-87-1 CAPLUS
 CN Pyridine, 2-[2-(2',5,6'-trifluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-89-3 CAPLUS

CN [1,1'-Biphenyl]-3-methanol, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605650-91-7 CAPLUS

CN Pyridine, 2-[2-(2'-methoxy-5'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-93-9 CAPLUS

CN Pyridine, 2-[2-[2'-(methylthio)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605650-95-1 CAPLUS

CN Acetamide, N-[3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 605650-97-3 CAPLUS

CN [1,1'-Biphenyl]-2-methanamine, N,N-dimethyl-3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605650-99-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 605651-01-2 CAPLUS

CN Pyridine, 2-[2-(2',5'-dichloro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-03-4 CAPLUS

CN Pyridine, 2-[2-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-13-6 CAPLUS

CN Pyridine, 2-[2-(2-methoxy-2'-methyl[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-15-8 CAPLUS

CN Pyridine, 2-[2-(4'-fluoro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-17-0 CAPLUS

CN Pyridine, 2-[2-(2,4'-dimethoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-19-2 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 605651-21-6 CAPLUS
 CN Pyridine, 2-[2-[3-methoxy-4-(4-pyridinyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-23-8 CAPLUS
 CN Pyridine, 2-[2-(2'-chloro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605651-25-0 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxaldehyde, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605651-27-2 CAPLUS
 CN Pyridine, 2-[2-(2,3'-dimethoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-28-3 CAPLUS

CN Pyridine, 2-[2-(2-methoxy-3'-methyl[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-30-7 CAPLUS

CN Pyridine, 2-[2-[3-methoxy-4-(1-naphthalenyl)phenyl]-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-32-9 CAPLUS

CN Ethanone, 1-[2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-
biphenyl]-3-yl]- (CA INDEX NAME)




RN 605651-33-0 CAPLUS

CN Pyridine, 2-[2-(3'-fluoro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-34-1 CAPLUS

CN Pyridine, 2-[2-(2',4'-difluoro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-36-3 CAPLUS

CN [1,1'-Biphenyl]-2-ol, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
(CA INDEX NAME)




RN 605651-37-4 CAPLUS


CN Pyridine, 2-[2-(2'-fluoro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-38-5 CAPLUS
 CN Pyridine, 2-[2-(2-methoxy-2',3'-dimethyl[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-40-9 CAPLUS
 CN Pyridine, 2-[2-(2',5'-difluoro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605651-42-1 CAPLUS
 CN Ethanone, 1-[2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-2-yl]- (CA INDEX NAME)




RN 605651-43-2 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605651-47-6 CAPLUS

CN Pyridine, 2-[2-(3'-ethoxy-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-49-8 CAPLUS

CN Quinoline, 8-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA
INDEX NAME)




RN 605651-50-1 CAPLUS


CN [1,1'-Biphenyl]-2-methanamine, 2'-methoxy-N,N-dimethyl-4'-[5-(2-pyridinyl)-
2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605651-51-2 CAPLUS
 CN Pyridine, 2-[2-(2',4'-dichloro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-52-3 CAPLUS
 CN Pyridine, 2-[2-(2',6'-dichloro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605651-54-5 CAPLUS
 CN Pyrimidine, 5-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)




RN 605651-55-6 CAPLUS
 CN Pyridine, 2-[2-[2-methoxy-2'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-4-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-56-7 CAPLUS

CN Pyridine, 2-[2-[2-methoxy-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-57-8 CAPLUS

CN [1,1'-Biphenyl]-3-methanol, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)




RN 605651-88-5 CAPLUS

CN Pyridine, 2-[2-(4'-methoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605651-89-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 605651-90-9 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-4'-methoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-91-0 CAPLUS

CN Pyridine, 2-[2-(5-fluoro-3'-methyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605651-92-1 CAPLUS

CN Pyridine, 2-[2-[3-fluoro-5-(1-naphthalenyl)phenyl]-2H-tetrazol-5-yl]- (CA
INDEX NAME)




RN 605651-93-2 CAPLUS


CN Pyridine, 2-[2-(5-fluoro-2',6'-dimethoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-
5-yl]- (CA INDEX NAME)




RN 605651-94-3 CAPLUS
 CN [1,1'-Biphenyl]-3-ol, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
 (CA INDEX NAME)




RN 605651-95-4 CAPLUS
 CN Pyridine, 2-[2-(2'-ethyl-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605651-96-5 CAPLUS
 CN Pyridine, 2-[2-(4'-chloro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA
 INDEX NAME)




RN 605651-97-6 CAPLUS
 CN Pyridine, 2-[2-[3-(1-naphthalenyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX
 NAME)




RN 605651-98-7 CAPLUS
 CN Pyridine, 2-[2-(2',4'-dimethoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605651-99-8 CAPLUS
 CN Pyridine, 2-[2-(2',6'-dimethoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)



RN 605652-00-4 CAPLUS
 CN Pyridine, 2-[2-(2',6'-dimethyl[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605652-01-5 CAPLUS
 CN [1,1'-Biphenyl]-4-amine, N,N-dimethyl-3'--[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
 (CA INDEX NAME)




RN 605652-02-6 CAPLUS

CN Pyridine, 2-[2-[3-(1,3-benzodioxol-5-yl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-03-7 CAPLUS

CN Pyridine, 2-[2-(3'-ethoxy-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-04-8 CAPLUS

CN Pyridine, 2-[2-(2',5'-dichloro-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-05-9 CAPLUS


CN Pyridine, 2-[2-(2',4'-dichloro-5-fluoro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-06-0 CAPLUS
 CN Pyridine, 2-[2-(5-fluoro[1,1':2'',1'''-terphenyl]-3-yl)-2H-tetrazol-5-yl]-
 (9CI) (CA INDEX NAME)



RN 605652-07-1 CAPLUS
 CN Pyridine, 2-[2-[5-fluoro-2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605652-08-2 CAPLUS
 CN Pyridine, 2-[2-[3-(1-dibenzofuranyl)-5-fluorophenyl]-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605652-09-3 CAPLUS

CN Methanesulfonamide, N-[3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 605652-10-6 CAPLUS

CN Pyridine, 2-[2-[5-fluoro-2'-(phenylmethoxy)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-11-7 CAPLUS

CN Pyridine, 2-[2-[5-fluoro-2'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-12-8 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-fluoro-5'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 605652-13-9 CAPLUS

CN Pyridine, 2-[2-[5-fluoro-3'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-14-0 CAPLUS

CN Pyridine, 5-[3-fluoro-5-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 605652-15-1 CAPLUS

CN Pyridine, 2-[2-(3'-ethoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-16-2 CAPLUS

CN Pyridine, 2-[2-(2'-ethoxy[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-17-3 CAPLUS

CN Acetamide, N-[3'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 605652-18-4 CAPLUS

CN Pyridine, 2-[2-(2',4'-dichloro[1,1'-biphenyl]-3-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605652-19-5 CAPLUS

CN Pyridine, 2-(2-[1,1':2',1''-terphenyl]-3-yl)-2H-tetrazol-5-yl)- (9CI) (CA
INDEX NAME)




RN 605652-20-8 CAPLUS

CN Pyridine, 2-[2-[3-(1-dibenzofuranyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX
NAME)




RN 605652-21-9 CAPLUS

CN Pyridine, 2-[2-[3-(4-dibenzofuranyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX
NAME)




RN 605652-22-0 CAPLUS

CN Pyridine, 2-[2-(4'-chloro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605652-23-1 CAPLUS

CN Pyridine, 2-[2-(2-methoxy-3'-nitro[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605652-24-2 CAPLUS

CN Pyridine, 2-[2-(2-methoxy-4'-methyl[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605652-25-3 CAPLUS


CN Pyridine, 2-[2-(3'-chloro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605652-26-4 CAPLUS
 CN Pyridine, 2-[2-(2',3'-dichloro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605652-27-5 CAPLUS
 CN Pyridine, 2-[2-(2,2',4'-trimethoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




IT 605652-28-6P 605652-29-7P 605652-30-0P
 605652-31-1P 605652-32-2P 605652-33-3P
 605652-34-4P 605652-35-5P 605652-36-6P
 605652-37-7P 605652-38-8P 605652-39-9P
 605652-40-2P 605652-41-3P 605652-42-4P
 605652-43-5P 605652-44-6P 605652-45-7P
 605652-46-8P 605652-47-9P 605652-48-0P
 605652-49-1P 605652-50-4P 605652-51-5P
 605652-52-6P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (preparation of diaryltetrazoles as inhibitors of metabotropic glutamate
 receptor-5)
 RN 605652-28-6 CAPLUS
 CN Pyridine, 2-[2-(2,2',6'-trimethoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605652-29-7 CAPLUS
 CN [1,1'-Biphenyl]-3-ol, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
 (CA INDEX NAME)



RN 605652-30-0 CAPLUS
 CN Pyridine, 2-[2-(2-methoxy-2',6'-dimethyl[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605652-31-1 CAPLUS
 CN Pyridine, 2-[2-(2-methoxy-2',5'-dimethyl[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
 (CA INDEX NAME)




RN 605652-32-2 CAPLUS
 CN Pyridine, 2-[2-(2'-ethyl-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-


(CA INDEX NAME)




RN 605652-33-3 CAPLUS
CN Pyridine, 2-[2-[4-(1,3-benzodioxol-5-yl)-3-methoxyphenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-34-4 CAPLUS
CN Acetamide, N-[2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 605652-35-5 CAPLUS
CN Acetamide, N-[2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)




RN 605652-36-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 605652-37-7 CAPLUS

CN Pyridine, 2-[2-(2',5'-dichloro-2-methoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-38-8 CAPLUS

CN Pyridine, 2-[2-(2-methoxy[1,1':2',1''-terphenyl]-4-yl)-2H-tetrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 605652-39-9 CAPLUS


CN Pyridine, 2-[2-[2-methoxy-2'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605652-40-2 CAPLUS


CN Pyridine, 2-[2-[4-(1-dibenzofuranyl)-3-methoxyphenyl]-2H-tetrazol-5-yl]-

(CA INDEX NAME)




RN 605652-41-3 CAPLUS

CN Pyridine, 2-[2-[4-(4-dibenzofuranyl)-3-methoxyphenyl]-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605652-42-4 CAPLUS


CN Pyridine, 2-[2-(2-methoxy-2'-phenoxy[1,1'-biphenyl]-4-yl)-2H-tetrazol-5-yl]-
(CA INDEX NAME)




RN 605652-43-5 CAPLUS
 CN Methanesulfonamide, N-[2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl][1,1'-biphenyl]-2-yl]- (CA INDEX NAME)




RN 605652-44-6 CAPLUS
 CN Pyridine, 2-[2-[2-methoxy-2'-(phenylmethoxy)[1,1'-biphenyl]-4-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-45-7 CAPLUS
 CN Pyridine, 2-[2-[3-methoxy-4-(1-thianthrenyl)phenyl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-46-8 CAPLUS
 CN Pyridine, 2-[2-[2-methoxy-2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-47-9 CAPLUS
 CN Pyridine, 2-[2-[2-methoxy-3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-4-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-48-0 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-methoxy-4'-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 605652-49-1 CAPLUS
CN Pyridine, 2-[2-[2-methoxy-3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-2H-tetrazol-5-yl]- (CA INDEX NAME)




RN 605652-50-4 CAPLUS
CN Pyridine, 2-methoxy-5-[2-methoxy-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (CA INDEX NAME)



RN 605652-51-5 CAPLUS
CN Pyridine, 2-[2-(3,5-di-3-pyridinylphenyl)-2H-tetrazol-5-yl]- (CA INDEX NAME)



RN 605652-52-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2'-amino-4-[5-(2-pyridinyl)-2H-tetrazol-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	39.11	217.68
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.60	-5.60

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:03:45 ON 27 MAY 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 10:37:28 ON 27 MAY 2008
FILE 'CAPLUS' ENTERED AT 10:37:28 ON 27 MAY 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	39.11	217.68
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.60	-5.60

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	39.11	217.68
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.60	-5.60

10506479.trn

FILE 'REGISTRY' ENTERED AT 10:37:37 ON 27 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1
DICTIONARY FILE UPDATES: 26 MAY 2008 HIGHEST RN 1022798-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10506479\Struc 2.str



```

chain nodes :
19
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
chain bonds :
1-6 4-12
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14
14-15 15-16 16-17
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 4-5
exact bonds :
4-12
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

```


G1:Cb,Cy,Hy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 20:Atom

L5 STRUCTURE UPLOADED

=> d

L5 HAS NO ANSWERS

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> 15

SAMPLE SEARCH INITIATED 10:38:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 58 TO ITERATE

100.0% PROCESSED 58 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 704 TO 1616

PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> 15 full

FULL SEARCH INITIATED 10:38:07 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 956 TO ITERATE

100.0% PROCESSED 956 ITERATIONS 2 ANSWERS

SEARCH TIME: 00.00.01

L7 2 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	396.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.60

FILE 'CAPLUS' ENTERED AT 10:38:12 ON 27 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 26 May 2008 (20080526/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> 17

L8 1 L7

=> d ibib abs hitstr 1

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:757524 CAPLUS

DOCUMENT NUMBER: 139:276903

TITLE: Preparation of diaryltetrazoles as modulators of metabotropic glutamate receptor-5

INVENTOR(S): Smith, Nicholas D.; Cosford, Nicholas D. P.; Reger, Thomas R.; Roppe, Jeffrey R.; Poon, Steven F.; Huang, Dehua; Chen, Chixu; Eastman, Brian W.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 170 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077918	A1	20030925	WO 2003-US7074	20030307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478799	A1	20030925	CA 2003-2478799	20030307
AU 2003213783	A1	20030929	AU 2003-213783	20030307
AU 2003213783	B2	20070125		

EP 1485093 A1 20041215 EP 2003-711474 20030307
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2005526081 T 20050902 JP 2003-575971 20030307
 US 20050153986 A1 20050714 US 2004-506479 20040901
 PRIORITY APPLN. INFO.: US 2002-363456P P 20020312
 WO 2003-US7074 W 20030307
 OTHER SOURCE(S): MARPAT 139:276903
 GI




AB Tetrazoles I [A, B = alkylene, optionally interrupted by heteroatoms; X, Y = (un)substituted heteroaryl, at least one of which has N adjacent to the attachment to A or B] are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. I $IC_{50} \leq 10 \mu M$ in the calcium flux assay and $\leq 100 \mu M$ in the phosphatidylinositol hydrolysis assay. Thus, 1-(3-aminophenyl)-3-methyl-2-imidazolidinone was diazotized and treated with 2-pyridinecarboxaldehyde and 4-MeC₆H₄SO₂NHNH₂ to give the tetrazole II.


IT 605647-82-3P 605648-18-8P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of diaryltetrazoles as inhibitors of metabotropic glutamate receptor-5)

RN 605647-82-3 CAPLUS

CN Pyridine, 2-[2-[3-fluoro-5-(3-pyridinyloxy)phenyl]-2H-tetrazol-5-yl]-6-phenyl- (CA INDEX NAME)



RN 605648-18-8 CAPLUS
 CN Benzonitrile, 3-fluoro-5-[5-(5-phenyl-2-pyridinyl)-2H-tetrazol-2-yl]- (CA
 INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

5.93	401.97
------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-0.80	-6.40
-------	-------

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:38:30 ON 27 MAY 2008